管理層發言
Good day, and welcome to the Bionano Second Quarter 2026 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.
Thank you, operator, and good afternoon, everyone. Welcome to the Bionano Second Quarter 2026 Financial Results Conference Call. On the call today are Dr. Albert A. Luderer, Chairman and Interim CEO of Bionano, and Mark Adamchak, Bionano's Vice President of Accounting and Principal Accounting Officer. After the market closed today, Bionano issued a press release announcing its financial results for the second quarter of 2026. A copy of the release can be found on the Investor Relations page of the company's website. Certain statements made during this conference call may be forward-looking statements. Actual results may differ materially from such statements due to several factors and risks, some of which are identified in Bionano's press release and Bionano's reports filed with the SEC. These forward-looking statements are based upon information available to Bionano today, 08/10/2026, and the company assumes no obligation to update statements as circumstances change. During our call, we may reference certain non-GAAP financial measures we believe provide useful information for investors. Reconciliations of these measures to GAAP can be found in our press release and in our slide deck. An audio recording and webcast replay of today's conference call will also be available online on the Investor Relations page of the company website. With that, I will turn the call over to Albert.
Well, thank you, Webb, and good afternoon, everyone. I am pleased to be here with you all today to share our second quarter 2026 results. Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers. Our results reflect a vote of confidence from our routine use customer community and the accelerating global adoption of optical genome mapping, or OGM. Importantly, the growth of our consumable sales this quarter was primarily driven by increased clinical adoption. We expect that adoption together with increased utilization at existing and new clinical sites to remain the foundation of our growth. Now before I get into the quarter, I want to note an important addition to our team. We are pleased to welcome back Dr. Alex Hastie as our Chief Scientific Officer. Alex was one of the original architects of our technology. He spent 14 years building Bionano's leadership in OGM, and he is widely regarded across our community as, and I quote, 'Mr. Optical Genome Mapping.' His return underscores our commitment to scientific leadership as we expand the commercial and clinical research applications of our platform. I also wanted to provide a very brief update on the ongoing search for my replacement. I am working in lockstep with the board to identify the best candidate to take Bionano into its next stage of growth. Until then, I remain solely committed to Bionano, our customers, employees, and our shareholders. As a reminder, our focus remains on transforming pathology, the discipline that investigates the causes, development, and effects of disease. Legacy analog workflows are tedious, slow, costly, and labor intensive. We are spearheading a shift to streamlined digital workflows based on technology and platform consolidation, automation, and the AI-driven software behind our products and solutions. Today, I will walk through the progress we are making against our strategy to transform pathology. I want to briefly recap the framework that continues to guide our execution. Beginning in September 2024, we deliberately redirected our focus away from aggressive installed base expansion towards driving profitable growth with existing routine users. We are achieving this by being selective about new customer acquisition, prioritizing prospects most likely to become routine, high-volume users. Four strategic pillars define how we have and will continue to execute against that framework. First, to support and sustain our installed base of routine OGM and VIA software use. Second, to increase OGM utilization by routine users by supporting menu expansion and improving ease of use with VIA and Ionic adoption. Third, to build the support needed for OGM reimbursement and inclusion in medical society guidelines and recommendations. And fourth, to improve profitability and scalability through lower costs, higher volumes, and continuous improvement in product quality. Turning to our first and second pillars, which are focused on supporting our installed base and driving greater utilization of our products: Q2 2026 flow cell sales were up 27% year over year at a record 9.22 thousand units. Demand continues to outpace our supply, although we are making progress working down our backlog. Removing flow cell sales tied to sales of new OGM systems in both periods, flow cells sold to existing customers were up 24% year over year in Q2. Simply put, our customers are running more samples, and much of that pull-through reflects increasing clinical adoption of OGM. Breaking down our revenue segments, consumable revenue was $4.3 million in Q2, up 30% year over year. That growth came primarily from an increase in the number of flow cells sold, consistent with the clinical adoption trend I just mentioned—the clearest evidence of our strategy in action. Software revenue was $1.4 million in Q2, down 16% year over year, reflecting timing delays in deployment from certain customers. Other revenue, which includes instruments and services, was $2.5 million in Q2, up 38% year over year, led by higher instrument sales as new customers came onto the platform. This ongoing shift towards a higher proportion of recurring consumable-led revenue reflects a healthier, more predictable business mix in our view and is directly aligned with our strategy. I would also note that international markets continue to be a key growth driver in the quarter, with international revenue now representing the majority of our total revenue. We attribute this to broadening clinical adoption at leading European institutions. Regarding our second pillar, driving greater utilization of our product, we ended the quarter with 397 OGM systems installed worldwide, up 5% from 378 a year ago. At the same time, flow cells sold were up 27% year over year at 9.22 thousand units, a record for any quarter even as demand continues to outpace what we can currently supply. Together, these two data points capture exactly what we are focused on: meaningfully deepening flow cell utilization within a robust footprint of OGM systems. Expanding on the second pillar, increasing OGM utilization by supporting software adoption and menu expansion, we continue to receive very positive feedback on our software and compute upgrades, which enable customers to expand their menus and increase utilization—in some cases doubling weekly cancer sample throughput without any hardware change. VIA's reach extends well beyond OGM; it remains the gold standard for CNV analysis on microarrays, and adoption among NGS and long-read sequencing labs continues to grow. These non-OGM VIA users represent both a durable software revenue stream and a natural entry point into broader Bionano adoption. We also continue to develop and support our Ionic system, which represents a fundamentally different approach to nucleic acid purification. Rather than relying on the bead- and column-based binding and washing steps that have defined the space for the last two decades, Ionic separates and concentrates DNA and RNA directly in solution. We are specifically expanding Ionic's capabilities to interface directly with sample preparation for OGM and long-read sequencing, with the OGM expansion targeted for launch in Q4 of 2026. In our view, it will be an important contributor to incremental consumables revenue and deeper customer relationships, supporting the higher-margin recurring revenue mix at the center of our long-term growth strategy. Now regarding the third pillar, building support for OGM reimbursement and inclusion in medical society guidelines: the two Category I CPT codes that took effect earlier this year covering OGM in hematologic malignancies at $1,850 and OGM in constitutional genetic disorders at $1,260 now cover OGM's primary application areas and represent significant reimbursement infrastructure supporting routine adoption. What we are increasingly seeing this year is reimbursement infrastructure translating into real clinical adoption and utilization, which is, of course, the engine behind our consumable growth. This development continues to reduce barriers to adoption and pave the way for even more routine use of OGM across oncology and clinical genetics research communities globally. On the publications and evidence front, momentum continued in the second quarter, and the evidence base is increasingly clinical in nature. First, in May, we announced the largest OGM study of T-cell acute lymphoblastic leukemia, or T-ALL, to date, published in Modern Pathology and conducted by researchers at the University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine. Across 91 cases, OGM detected genomic abnormalities in 97.8% of cases, compared to just 55% by conventional karyotyping, and delivered clinically relevant genomic information beyond karyotyping in approximately 70% of cases from a single workflow. T-ALL is an aggressive blood cancer where roughly half of cases remain unsolved by legacy methods, and this study demonstrates how well suited OGM is to that challenge. Second, we announced multiple Q2 2026 publications describing the unique utility of OGM in reproductive health and prenatal genetic disorders, with 13 studies analyzing 730 subjects published to date—an important expansion of OGM's evidence base into a large new application area. Third, at the 2026 European Society of Human Genetics Conference, studies featuring OGM increased 67% year over year, with representation from 17 countries, up from 12 in 2025—a strong signal of the global breadth of the OGM research community. These studies join landmark multiple myeloma studies from Johns Hopkins and MD Anderson published in the American Journal of Hematology, which we highlighted last quarter and which demonstrated that OGM can significantly outperform traditional methods for detecting structural variations and chromosomal abnormalities. Taken together, we believe this expanding, increasingly clinical body of evidence is a leading indicator of future adoption and utilization of OGM. Regarding our fourth pillar, we are pleased to report progress on our goal to reach profitability. From a high 20% gross margin profile in 2023, we have steadily driven that figure higher over the past several years, reaching 53% in Q2 2026—our highest quarterly gross margin to date. We have reduced operating expenses with the same disciplined philosophy. As revenue scales and our mix continues to tilt towards higher-margin consumables and software, we expect these trends to carry us towards adjusted EBITDA breakeven over time, a key milestone we are focused on as we build towards sustainable profitability. Additionally, I am happy to share that in the second quarter we fully retired our outstanding senior secured convertible debt, further simplifying our financial profile. I will now turn the call over to Mark Adamchak, our Principal Accounting Officer, to review our Q2 2026 financial highlights and discuss our expectations for Q3 and the full year 2026. Mark?
Thanks, Albert. Revenue for the second quarter of 2026 was $8.2 million, up 21% compared to Q2 2025, and above our guidance range of $7.5 million to $7.8 million. We sold 9.22 thousand nanochannel array flow cells, up 27% compared to Q2 2025, despite ongoing supply constraints as consumable demand continued to outpace our current manufacturing capacity. Turning to profitability: adjusted gross margin for the second quarter of 2026 was 53%, compared to 52% in Q2 2025, reflecting continued operational efficiencies under our strategy. Second quarter 2026 adjusted operating expense was $8.7 million compared to $8.8 million in Q2 2025. We ended the quarter with $10.4 million in cash, cash equivalents, and available-for-sale securities, including $500 thousand subject to certain restrictions. Based on factors described in our 10-Q, we expect our cash runway to extend at least into the first quarter of 2027. We also note that during the second quarter, we completed the full retirement of our outstanding senior secured convertible debt, which marked a meaningful balance sheet milestone that further simplifies our financial profile. Building on this progress, we expect revenue to grow throughout the year as we continue executing on our plan. For the full year 2026, we are raising the low end of our revenue guidance range to $31 million to $33 million, representing growth of 9% to 16% over 2025. For Q3 2026, we are initiating guidance of $8.2 million to $8.6 million, representing 11% to 16% growth over Q3 2025. We are very excited about the work and the journey ahead of us at Bionano. With that, I will turn the call back to the operator for Q&A.
分析師問答
Certainly. As a reminder, to ask a question, please press the appropriate key. Our first question will be coming from the line of Yi Chen of H.C. Wainwright & Company. Your line is open, Yi.
Hi. Thank you for taking my questions. You mentioned that you are raising the lower end of the revenue guidance for 2026. Could you tell us why the higher end is not raised as well?
Thank you for the question. We are very much constrained in terms of our flow cell manufacturing capacity. As we mentioned earlier in the call, we are backordered, and we hope to remedy that by the middle to the end of the fourth quarter. So we are reluctant to raise the top line until we know for certain that our manufacturing can keep up with demand.
I see. And your guidance for the third quarter could be essentially flat compared to the second quarter, or maybe show a small sequential growth, while your second quarter demonstrated pretty robust sequential growth over the first quarter. So is there seasonality involved, or is it also related to manufacturing?
It is actually caused by several very large orders that are very close to the end of the third quarter, and we thought they were at risk. So we were conservative in our outlook regarding whether we would close them this quarter or next quarter.
Okay. Got it. And last thing: could you give some additional color regarding whether the current growth observed in the second quarter is primarily driven by increased utilization within existing clients or by new clients acquired during the quarter?
The majority of our growth is coming from existing clients. It is very strong demand, especially from our clinical users. That is where the majority of the growth is coming from.
And do you expect the same for the coming quarters—that the majority of growth will be coming from existing clients?
Yes. I believe that will be the case. We have tremendous demand, and we are looking forward to meeting that demand.
Thank you, Yi. Our next question will be coming from the line of Jason McCarthy of Maxim Group. Your line is open.
Hey, guys. This is Michael on the line. Thank you so much for taking my questions today. I wanted to see if any of the growth you have seen in unit and consumables placements, or in terms of revenue, has been driven by the new pricing on the CPT code in hematology, or if we are still expecting that to take some more time to materialize? Also, in terms of the constitutional genetics application, are there any efforts ongoing to get reimbursement to reach a similar level to hematology? Because I believe that is still the same level that hematology used to be at before you got the improved CPT code pricing. And then, just one last financial-related question: looking at the sequential growth, the number of consumables sold during the quarter seems to have significantly outpaced the change in consumables revenue on a sequential basis between Q1 and Q2. Could you provide a little bit of context on what is driving that?
That's a great question. Right now, we think the CPT change is starting to drive sales, and time will tell how that evolves. We believe it's having an impact here in the United States, and we also see that trend occurring in Europe where different regions are starting to gain coverage, so it is a meaningful development. Regarding constitutional genetics reimbursement, there was some effort to change that, but I do not think there has been progress to reach the same level as hematology yet.
Got it. On the consumables revenue question, Mark, would you like to take a shot at explaining the apparent disconnect between flow cells sold and consumables revenue growth?
Sure. You have to remember that we have a substantial portion of our customers on reagent rental agreements. So it is not a one-to-one ratio of flow cells sold to revenue dollars. A portion of the revenue for those arrangements gets deferred and amortized over the life of the lease, and that primarily explains the difference between the growth in units sold and the change in consumables revenue on a sequential basis.
Thank you very much. I appreciate the additional color, and congrats on the great progress you guys are making.
Thank you for your questions. This concludes today's conference call. Thank you for your participation. You may now disconnect.